在多发性硬化症中停止使用ocrelizumab后,疾病活动的复发
E Coerver1, L Schoof1, L Hogenboom1
1MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, Netherlands.
Multiple sclerosis and related disorders
|October 6, 2024
概括
在停止治疗多发性硬化症 (MS) 的ocrelizumab (OCR) 治疗后,疾病复发率似乎很低,特别是在复发性复发性MS (RRMS) 中. 然而,停止OCR可能不适合所有患者,需要进一步研究其免疫复原潜力.
科学领域:
- 神经免疫学 神经免疫学
- 临床神经学 临床神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥克雷利祖马布 (OCR) 是一种有效的多发性硬化症 (MS) 治疗方法,具有作为免疫复原疗法的潜力.
- 有限的数据存在于OCR停止后的疾病复发.
- 了解复发对于评估OCR的长期治疗策略至关重要.
研究的目的:
- 评估在MS患者中停止ocrelizumab治疗后疾病活动复发的速率和特征.
- 评估OCR discontinuation作为潜在的免疫复制策略的安全性和有效性.
主要方法:
- 一项多中心回顾性队列研究包括53名多发性硬化症患者,这些患者停止了OCR治疗≥12个月.
- 焦点炎症被定义为临床复发或显著的MRI活动 (≥3个新的T2病变或≥2个增强对比度的病变).
- 在停止治疗之前,患者至少接受了一剂600毫克的OCR剂量.
主要成果:
- 停药后的焦点炎症仅在复发性缓解性多发性硬化症 (RRMS) 患者中观察到 (n=41).
- 9.8% (4/41) 的RRMS患者在输液后17个月的中位数经历了焦点炎症.
- 这包括1例放射性确认病例和3例怀疑没有放射性活性的临床复发.
结论:
- 在MS中停止OCR治疗后,焦点炎症的复发率似乎很低 (在RRMS中为9.8%).
- 停止使用ocrelizumab可能不适合所有多发性硬化患者.
- 需要进行更大规模的研究,才能充分确定OCR的免疫复合疗法潜力.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:30Inflammatory Bowel Disease II: Crohn's Disease
194
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
194
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:29Autoimmune Disorders
394
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
394